Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data

INTRODUCTION: SB4 is the first approved biosimilar of etanercept, a biologic tumor necrosis factor inhibitor, to treat various autoimmune diseases including axial spondylarthritis (axSpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and plaque psoriasis (PsO). This post-marketing surveilla...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Wan-Hee, Kang, Young Mo, Kim, Dong Wook, Kang, Eun Ha, Lee, Yeon-Ah, Suh, Chang-Hee, Sung, Yoon-Kyoung, Lee, Sang-Hoon, Gu, Dong-Ha, Lee, Jiwon, Choe, Jung-Yoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011358/
https://www.ncbi.nlm.nih.gov/pubmed/36482248
http://dx.doi.org/10.1007/s40744-022-00515-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011358/
https://www.ncbi.nlm.nih.gov/pubmed/36482248
http://dx.doi.org/10.1007/s40744-022-00515-z

Ejemplares similares